

Andrea Giuffrida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4202365/publications.pdf>

Version: 2024-02-01

76
papers

7,781
citations

81743

39
h-index

91712

69
g-index

76
all docs

76
docs citations

76
times ranked

6153
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential effects of δ^9 -tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model. <i>PLoS ONE</i> , 2020, 15, e0230238.	1.1	15
2	Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat. <i>Schizophrenia Research</i> , 2019, 206, 263-270.	1.1	12
3	Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 393-403.	1.0	22
4	The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release. <i>Neuropharmacology</i> , 2018, 130, 1-9.	2.0	13
5	Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia. <i>Behavioural Pharmacology</i> , 2017, 28, 512-520.	0.8	3
6	The Endocannabinoid System and Parkinson Disease. , 2017, , 63-81.		4
7	Role of the satiety factor oleoylethanolamide in alcoholism. <i>Addiction Biology</i> , 2016, 21, 859-872.	1.4	58
8	Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease. <i>Experimental Neurology</i> , 2016, 286, 83-92.	2.0	75
9	Distinct neuronal activation patterns are associated with PCP-induced social withdrawal and its reversal by the endocannabinoid-enhancing drug URB597. <i>Neuroscience Research</i> , 2016, 110, 49-58.	1.0	20
10	Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system. <i>European Neuropsychopharmacology</i> , 2016, 26, 298-309.	0.3	22
11	THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 169-181.	2.0	14
12	Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia. <i>Neuropsychopharmacology</i> , 2016, 41, 477-486.	2.8	25
13	Simultaneous Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase Shares Discriminative Stimulus Effects with δ^9 -Tetrahydrocannabinol in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 353, 261-268.	1.3	22
14	Nonclassic Signaling in the Brain. , 2014, , 239-255.		0
15	The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 153-159.	1.3	40
16	Cannabinoids and Levodopa-Induced Dyskinesia. , 2014, , 245-264.		1
17	Exercise-induced endocannabinoid signaling is modulated by intensity. <i>European Journal of Applied Physiology</i> , 2013, 113, 869-875.	1.2	138
18	Phencyclidine-Induced Social Withdrawal Results from Deficient Stimulation of Cannabinoid CB1 Receptors: Implications for Schizophrenia. <i>Neuropsychopharmacology</i> , 2013, 38, 1816-1824.	2.8	71

#	ARTICLE	IF	CITATIONS
19	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. , 2013, , 73-101.		1
20	Academia-Industry Partnerships as Incubators for Economic Development. Pharmaceutical Regulatory Affairs: Open Access, 2013, 02, .	0.2	0
21	Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. European Journal of Neuroscience, 2012, 36, 3224-3234.	1.2	40
22	Novel codrugs with GABAergic activity for dopamine delivery in the brain. International Journal of Pharmaceutics, 2012, 437, 221-231.	2.6	36
23	New insights on endocannabinoid transmission in psychomotor disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 51-58.	2.5	17
24	Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 260-269.	2.5	60
25	The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neuroscience Research, 2012, 72, 236-242.	1.0	53
26	Dyskinesia in Parkinson's Disease Therapy. Parkinson's Disease, 2012, 2012, 1-2.	0.6	0
27	Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the "runner's high". Journal of Experimental Biology, 2012, 215, 1331-1336.	0.8	187
28	Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. Hormones and Behavior, 2011, 60, 617-624.	1.0	32
29	Inhibition of fatty acid amide hydrolase modulates anxiety-like behavior in PCP-treated rats. Pharmacology Biochemistry and Behavior, 2011, 98, 583-586.	1.3	10
30	Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. International Journal of Neuropsychopharmacology, 2010, 13, 373.	1.0	86
31	A synthetic cannabinoid agonist promotes oligodendroglialogenesis during viral encephalitis in rats. Experimental Neurology, 2010, 226, 231-241.	2.0	33
32	In vivo pharmacology of endocannabinoids and their metabolic inhibitors: Therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins and Other Lipid Mediators, 2010, 91, 90-103.	1.0	31
33	Chapter 6 The Endocannabinoid System During Development: Emphasis on Perinatal Events and Delayed Effects. Vitamins and Hormones, 2009, 81, 139-158.	0.7	70
34	Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. British Journal of Psychiatry, 2009, 194, 371-372.	1.7	157
35	Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. Journal of Neural Transmission, 2009, 116, 301-305.	1.4	41
36	WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. European Journal of Neuroscience, 2009, 29, 2177-2186.	0.2	202

#	ARTICLE	IF	CITATIONS
37	Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801. <i>Behavioural Brain Research</i> , 2009, 204, 410-415.	1.2	88
38	Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. <i>Neurochemistry International</i> , 2009, 54, 56-64.	1.9	42
39	Androgens Induce Dopaminergic Neurotoxicity via Caspase-3-Dependent Activation of Protein Kinase C δ . <i>Endocrinology</i> , 2009, 150, 5539-5548.	1.4	67
40	Regulation of brain anandamide by acute administration of ethanol. <i>Biochemical Journal</i> , 2007, 404, 97-104.	1.7	101
41	Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB1 and TRPV1 receptors. <i>Experimental Neurology</i> , 2007, 208, 110-119.	2.0	173
42	Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. <i>Schizophrenia Research</i> , 2007, 94, 29-36.	1.1	219
43	Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. <i>Analytical Biochemistry</i> , 2007, 361, 162-168.	1.1	56
44	CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. <i>Journal of Neurochemistry</i> , 2007, 101, 389-396.	2.1	41
45	Quantification of endocannabinoids in rat biological samples by GC/MS: Technical and theoretical considerations. <i>Prostaglandins and Other Lipid Mediators</i> , 2006, 81, 106-112.	1.0	49
46	A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. <i>Experimental Neurology</i> , 2005, 194, 355-362.	2.0	24
47	Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms. <i>Neuropsychopharmacology</i> , 2004, 29, 2108-2114.	2.8	423
48	Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. <i>European Journal of Neuroscience</i> , 2003, 18, 1607-1614.	1.2	144
49	Release of Fatty Acid Amides in a Patient With Hemispheric Stroke. <i>Stroke</i> , 2002, 33, 2112-2114.	1.0	113
50	N-Acylethanolamines in human reproductive fluids. <i>Chemistry and Physics of Lipids</i> , 2002, 121, 211-227.	1.5	203
51	Evidence that anandamide-signaling regulates human sperm functions required for fertilization. <i>Molecular Reproduction and Development</i> , 2002, 63, 376-387.	1.0	127
52	An anorexic lipid mediator regulated by feeding. <i>Nature</i> , 2001, 414, 209-212.	13.7	646
53	Quantification of Bioactive Acylethanolamides in Rat Plasma by Electrospray Mass Spectrometry. <i>Analytical Biochemistry</i> , 2000, 280, 87-93.	1.1	152
54	The endocannabinoid system: a physiological perspective on its role in psychomotor control. <i>Chemistry and Physics of Lipids</i> , 2000, 108, 151-158.	1.5	50

#	ARTICLE	IF	CITATIONS
55	Bidirectional control of airway responsiveness by endogenous cannabinoids. <i>Nature</i> , 2000, 408, 96-101.	13.7	193
56	Endogenous cannabinoid signaling and psychomotor disorders. <i>Prostaglandins and Other Lipid Mediators</i> , 2000, 61, 63-70.	1.0	10
57	Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. <i>European Journal of Pharmacology</i> , 2000, 408, 161-168.	1.7	118
58	Reversal of Dopamine D ₂ Receptor Responses by an Anandamide Transport Inhibitor. <i>Journal of Neuroscience</i> , 2000, 20, 3401-3407.	1.7	220
59	The endocannabinoid system as a target for therapeutic drugs. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 218-224.	4.0	401
60	Reply: cannabinoid paths to anti-diarrheal drugs. <i>Trends in Pharmacological Sciences</i> , 2000, 21, 373.	4.0	1
61	Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. <i>Nature Neuroscience</i> , 1999, 2, 358-363.	7.1	731
62	Elevated endogenous cannabinoids in schizophrenia. <i>NeuroReport</i> , 1999, 10, 1665-1669.	0.6	414
63	Control of pain initiation by endogenous cannabinoids. <i>Nature</i> , 1998, 394, 277-281.	13.7	995
64	Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. <i>FEBS Letters</i> , 1998, 422, 373-376.	1.3	87
65	Endogenous Cannabinoid Signaling. <i>Neurobiology of Disease</i> , 1998, 5, 462-473.	2.1	155
66	Specific localization in the equatorial region of gp20, a 20 kDa sialylglycoprotein of the capacitated human spermatozoon acquired during epididymal transit which is necessary to penetrate zona-free hamster eggs. <i>Molecular Human Reproduction</i> , 1998, 4, 119-125.	1.3	37
67	Glycan chains play a role in the axonemal cytoskeleton disassembly activity of the 35 kDa glycoprotein of the spermathecal extract of <i>Eyprepocnemis plorans</i> (Insecta, Orthoptera). <i>Insect Biochemistry and Molecular Biology</i> , 1997, 27, 315-321.	1.2	1
68	Purification and properties of a 35 kDa glycoprotein from spermathecal extract of <i>eyprepocnemis plorans</i> (insecta, orthoptera) with axonemal cytoskeleton disassembly activity. <i>Insect Biochemistry and Molecular Biology</i> , 1996, 26, 347-354.	1.2	8
69	Secretory product of the lateral oviducts of <i>Baculum thaii</i> haus. (Phasmida: Phasmatidae) and its change during egg transit. <i>Arthropod Structure and Development</i> , 1996, 25, 369-379.	0.4	6
70	Changes in the sialylglycoconjugate distribution on the human sperm surface during in-vitro capacitation: partial purification of a 20 kDa sialylglycoprotein of capacitated spermatozoa. <i>Human Reproduction</i> , 1995, 10, 2755-2759.	0.4	29
71	Changes in the sialylglycoconjugate distribution on the human sperm surface during in-vitro capacitation: partial purification of a 20 kDa sialylglycoprotein of capacitated spermatozoa. <i>Molecular Human Reproduction</i> , 1995, 1, 369-373.	1.3	2
72	Changes in sperm tail of <i>Eyprepocnemis plorans</i> (Insects, Orthoptera) as a result of in vitro incubation in spermathecal extract. <i>Invertebrate Reproduction and Development</i> , 1993, 24, 47-52.	0.3	10

#	ARTICLE	IF	CITATIONS
73	Ultrastructural changes in sperm of <i>Eyrepocnemis plorans</i> (Charpentier) (Orthoptera:) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Development, 1993, 24, 1-6.	0.3	25
74	Ultrastructural rearrangements of the vitelline envelope during egg development in <i>Eyrepocnemis plorans</i> (Charp.) (Orthoptera, Acrididae). Bollettino Di Zoologia, 1992, 59, 239-243.	0.3	0
75	Connecting flagellar elements in the sperm of <i>Eyrepocnemis plorans</i> (Charpentier) (Orthoptera :) Tj ETQq1 1 0.784314 rgBT ₃ /Overlock 10 Tf 50	0.4	3
76	Ultrastructural features of chorion and micropyles in eggs of <i>Eyrepocnemis plorans</i> (Orthoptera,) Tj ETQq0 0 0 rgBT ₃ /Overlock 10 Tf 50	0.3	6